Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults  by Kester, Kent E. et al.
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In an  attempt  to  improve  the  efﬁcacy  of  the candidate  malaria  vaccine  RTS,S/AS02,  two  studies  were
conducted  in  1999  in  healthy  volunteers  of RTS,S/AS02  in  combination  with  recombinant  Plasmodium
falciparum  thrombospondin-related  anonymous  protein  (TRAP).  In a Phase  1  safety  and  immuno-
genicity  study,  volunteers  were  randomized  to receive  TRAP/AS02  (N =  10),  RTS,S/AS02  (N  =  10), or
RTS,S  + TRAP/AS02  (N =  20)  at 0,  1  and  6-months.  In a  Phase  2  challenge  study,  subjects  were  randomized  to
receive  either  RTS,S  +  TRAP/AS02  (N =  25)  or TRAP/AS02  (N =  10)  at 0  and  1-month,  or to  a challenge  control
group  (N  =  8).  In both  studies,  the  combination  vaccine  had  an  acceptable  safety  proﬁle  and was  acceptably
tolerated.  Antigen-speciﬁc  antibodies,  lymphoproliferative  responses,  and  IFN-  production  by ELISPOT
assay  elicited  with  the  combination  vaccine  were  qualitatively  similar  to  those  generated  by  the  single
component  vaccines.  However,  post-dose  2 anti-CS  antibodies  in  the  RTS,S  + TRAP/AS02  vaccine  recipi-
ents  were  lower  than  in  the  RTS,S/AS02  vaccine  recipients.  After  challenge,  10  of  11 RTS,S  +  TRAP/AS02
vaccinees,  5 of  5 TRAP/AS02  vaccinees,  and  8  of 8 infectivity  controls  developed  parasitemia,  with  median
pre-patent  periods  of  13.0,  11.0,  and  12.0  days,  respectively.  The  absence  of  any  prevention  or delay  of
parasitemia  by TRAP/AS02  suggests  no apparent  added  value  of  TRAP/AS02  as a candidate  vaccine. The
absence  of  signiﬁcant  protection  or  delay  of parasitemia  in the  11  RTS,S  +  TRAP/AS02  vaccine  recipients
contrasts  with  previous  2 dose  
tistically  signiﬁcant  differences
the challenge  study,  that  the  p
previously  observed  with  this
consider  employing  alternativ
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. Introduction
Adjuvanted RTS,S (RTS,S/AS), a candidate malaria vaccine con-
isting of the recombinant protein RTS,S, which is comprised of
equences of the circumsporozoite protein (CSP) and hepatitis B
urface antigen (HBsAg), is uniquely able to protect malaria-naïve
dult subjects after experimental malaria challenge against infec-
ion [1–5], and African adults and children exposed to diverse
trains against clinical and severe disease [6–11]. Other strate-
ies have been concurrently explored to improve the efﬁcacy of
djuvanted RTS,S, including formulation with more potent adju-
ants [12–14], prime-boost regimens with alternative vaccine
latforms expressing the CSP [15–18] and evaluation of other adju-
anted Plasmodium falciparum antigens [19–21] individually or in
ombination with RTS,S [22,23]. We  report two clinical evalua-
ions which aimed at improving adjuvanted RTS,S by combining
t with the recombinant thrombospondin related anonymous pro-
ein (TRAP) of P. falciparum,  PfTRAP [24]. PfTRAP is one of several
dhesive proteins [25] naturally expressed in sporozoite [26] and
epatic stages [27]. The candidacy of PfTRAP as a vaccine anti-
en is supported by several considerations. First, PfTRAP, like CSP,
inds speciﬁcally to sulfated glycoconjugates on hepatic cells [28],
uggesting an essential role in sporozoite infectivity, conﬁrmed
sing PfTRAP knockout parasites [29]. Second, immunization of
odents with PfTRAP analogs alone or in combination with CSP
rotects them against parasitemia after experimental challenge
ith infectious sporozoites [30,31]. Third, several Phase 2 trials of
 viral-vectored PfTRAP-based multi-antigen vaccine have consis-
ently delayed [32,33], and in some instances prevented [34], patent
arasitemia after experimental challenge with mosquito-borne
alaria.
We  present the initial Phase 1 study conducted to assess the
afety and immunogenicity of RTS,S/AS combined with PfTRAP, and
he subsequent Phase 2 study in malaria naïve adults to assess
afety, immunogenicity, and efﬁcacy.
. Methods
.1. Study subjects and eligibility
The Phase 1 trial was conducted in males or females 18–50 years
ld at the Clinique Notre-Dame de Grâce, Gosselies, Belgium. The
hase 2 challenge trial, conducted at the Walter Reed Army Institute
f Research (WRAIR), USA, enrolled male or females aged 18–45
ears, with no history of malaria or previous administration of an
nvestigational malaria vaccine. In both studies, subjects were eligi-
le if healthy as established by medical history, clinical examination
nd laboratory screening, and were seronegative for HBsAg and
epatitis C. The Phase 1 study started in 1998 and was  completed
n 1999 and the Phase 2 study was conducted and completed in
999 (see Supplementary Appendix).
.2. Study design
Subjects in the Phase 1, open trial, were randomized to
RAP/AS02, RTS,S/AS02 or TRAP + RTS,S/AS02 groups (ratio 1:1:2)
o receive 3 doses of vaccine administered at 0, 1, 6-months.
The Phase 2, double-blind, challenge trial was originally planned
o recruit subjects to 2 cohorts; the ﬁrst cohort to undergo sporo-
oite challenge after 2 doses and the second after 3 doses of study
accine. Due to lack of protective efﬁcacy of both vaccines in the
rst cohort, the second cohort was not enrolled. Subjects in cohort
 were randomized to receive 2 doses of RTS,S + TRAP/AS02 or
RAP/AS02 (ratio 2.5:1) at 0, 1-months, with sporozoite-infected
osquito challenge planned for 7–30 days after Dose 2. A second2 (2014) 6683–6691
randomization was  conducted prior to challenge (for details, see
Supplementary Appendix).
2.3. Vaccines
The two  recombinantly produced vaccine antigens, RTS,S and
TRAP, were manufactured by GlaxoSmithKline (GSK) Biologicals
(Rixensart, Belgium). The RTS,S vaccine antigen has been described
[12]. The TRAP antigen is a recombinant protein produced in, and
puriﬁed from, the culture supernatant of insect cells (Spodoptera
frugiperda Sf9 cell line) infected with a recombinant baculovirus
(AcMNPV). The baculovirus expresses a truncated form of the TRAP
gene derived from P. falciparum strain NF54 (clone 3D7). The ﬁnal
puriﬁed antigen consists of a 493 amino acid long polypeptide
comprising amino acids 26 (arginine/R) to 511 (lysine/K) of the
authentic TRAP protein, extended at its carboxy terminal end by
the addition of 7 histidine residues. The antigens (RTS,S/TRAP or
TRAP) were presented as lyophilized pellets in single dose vials.
Just before administration, each pellet was  reconstituted with liq-
uid AS02 Adjuvant System [12]. Subjects received 50 g RTS,S or
25 g TRAP or both 50 g of RTS,S and 25 g of TRAP together with
50 g MPL, and 50 g QS21 in an oil/water emulsion as a 0.5 mL
dose, by intramuscular injection.
2.4. Safety assessments
Local and systemic adverse events (AEs) were systematically
assessed using standardized criteria as previously reported [2] (see
Supplementary Appendix). All unsolicited reports of AEs occurring
within 30 days, and of reactogenicity within 4 days, of vaccina-
tion were recorded. Serious AEs (SAEs) were collected throughout
the study. Hematological and biochemical tests for safety eval-
uation were performed and any clinically signiﬁcant values
noted.
2.5. Assessment of humoral immune response
Antibodies (IgG) against the CS central repeat tetrapeptide epi-
topes were measured using ELISA with recombinant R32LR as the
capture antigen as described previously [35,36]. Antibodies against
TRAP were measured by ELISA using the vaccine antigen as the
capture antigen, and expressed as titers.
2.6. Assessment of CMI response
2.6.1. Peripheral blood mononuclear cell collection
For both studies, the peripheral blood mononuclear cells
(PBMCs) were separated from heparinized whole blood on a den-
sity gradient and stored in liquid nitrogen as described previously
[37].
2.6.2. Lymphoproliferative assay
Lymphoproliferative (LP) results were expressed as stimulation
indices (SI*) which are the ratio between the quantities of 3H-
thymidine incorporated by the cells in the presence of a speciﬁc
antigen and the ones incorporated by the cells cultured in medium
alone (for assay methodologies, see the Supplementary Appendix).
2.6.3. Antigen-stimulated IFN- and IL-5 secretion by PBMC
IFN- and IL-5 secretion by whole PBMC was  measured in super-natant harvested from antigen-stimulated PBMC after 120 h by
commercial ELISA kit (respectively IFN- EASIA®; Medgenix, Fleu-
rus, Belgium or Biosource International, Camarillo, CA). Further
detail is provided in the Supplementary Appendix.
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.6.4. Ex vivo IFN- and IL-4 ELISPOT assays
ELISPOT assays were conducted as previously described (see
upplementary Appendix) [5,38].
.7. Efﬁcacy assessment
Immunized volunteers and infectivity controls underwent stan-
ardized malaria challenge (day of challenge [DOC]) over 2
onsecutive days, ranging from 16 to 27 days, after the second
mmunization. Parasitemia was detected through daily blood ﬁlms
tarting 7 days post challenge; volunteers were censored at 30
ays post challenge if no parasitemia was detected. Volunteers who
eveloped parasitemia were treated with a standard oral course of
hloroquine (total 1500 mg  base given in divided doses: 600 mg
nitially followed by 300 mg  at 6, 24 and 48 h) under direct super-
ision.
.8. Statistical analyses
.8.1. Study cohorts
For the Phase 1 trial all analyses are presented for the intention
o treat (ITT) population which included all subjects who  received
t least 1 dose of study vaccine. For the Phase 2 trial, safety data are
resented for the ITT population and immunogenicity and efﬁcacy
ata for a modiﬁed ITT population, excluding volunteers receiving
accine subject to temperature deviations (see Section 3.1).
.8.2. Analysis of reactogenicity and safety
Summaries were calculated for the incidence, intensity, and
elationship of solicited and unsolicited AEs (see Supplementary
ppendix).
.8.3. Analysis of humoral immune responses
The percentage of subjects with seropositive levels of anti-CS
ntibodies (≥1 g/mL) was determined. Antibody titers were sum-
arized by GMT  with 95% CI. GMT  calculations were performed
y taking the anti-log of the mean of the log titer transforma-
ions. Anti-CS antibody titers of <1 g/mL were assigned a value
f 0.5 g/mL for the purpose of GMT  calculation. For each vaccine
roup, anti-TRAP antibody titers were described and GMTs with
5% CI were calculated; no 0 values were found.
.8.4. Analysis of cell mediated immune responses
Descriptive analyses in terms of LP response, expressed as stim-
lation indices (SI*), and measurements of IFN- and IL-5 secretion
n the culture supernatant of the stimulated cells, are shown for
he Phase 1 study. Results for ELISPOT assays were described as
pot forming cells per million for the Phase 2 study.
.8.5. Sample size
Both studies were designed to assess the safety, immunogenic-
ty and efﬁcacy (Phase 2 study only) of each individual vaccination
egimen, and not for the support of inter-group comparisons. Only
escriptive analysis was planned and the sample size was not sta-
istically computed.
.8.6. Analysis of efﬁcacy
Efﬁcacy was assessed by comparison of malaria incidence and
ime to onset of parasitemia. Fisher’s Exact test was used for the
omparison of malaria incidence between the control and each
reated group. A Kaplan–Meier analysis was performed on time
o onset of parasitemia, testing between the control and the two
reatment groups using the log-rank statistic.2 (2014) 6683–6691 6685
3. Results
3.1. Subject cohort
The study ﬂow for both trials is provided in Fig. 1.
In the Phase 1 study, 40 subjects were enrolled and randomized
(RTS,S/AS02 N = 10, TRAP/AS02 N = 10, RTS,S + TRAP/AS02 N = 20).
The mean age of subjects was  34.3 years (range: 19–48 years), 60%
were males and all were Caucasian.
In the Phase 2 study, 43 subjects were enrolled (RTS,S + TRAP/
AS02 N = 25, TRAP/AS02 N = 10, control N = 8). Thirteen recipients
of Dose 2 of RTS,S + TRAP/AS02 and 5 recipients of Dose 2 of
TRAP/AS02 inadvertently received vaccine that may have been
transiently stored at subzero temperatures. As temporary freez-
ing might have reduced the potency of the vaccine, these subjects
were excluded from participating in the malaria challenge. Of the
43 subjects enrolled, the mean age was 34.2 years (range: 20–45
years), 61% were males and the majority were Caucasian (49%) or
African–American (40%).
3.2. Safety outcomes
Transient pain at the injection site was  the most frequently
reported solicited local AE across vaccine groups in both studies,
occurring with a similar incidence in each vaccine group (after
87–100% of doses) (Table 1). The frequency of Grade 3 pain was
similar after vaccination across vaccine groups and studies (after
17–35% of doses). Grade 3 redness and swelling occurred after <7%
of doses in any vaccine group. All Grade 3 AEs resolved within
the initial 72-h follow-up period after each vaccination, with the
majority of symptoms resolved within the ﬁrst 24 h.
The most frequently reported solicited general symptom in the
Phase 1 study was  myalgia (after 47–63% of doses across groups)
and in the Phase 2 study fatigue (after 30–32% of doses across
groups). Grade 3 general AEs occurred after <7% of doses in any
vaccine group. In the Phase 1 study all Grade 3 symptoms were
considered to have a ‘probable’/‘suspected’ (PB/SU) relationship to
vaccination and in the Phase 2 study, one report of Grade 3 malaise
in a recipient of RTS,S + TRAP/AS02 was  judged to have a PB/SU
relationship to vaccination.
Unsolicited AEs with a PB/SU relationship to vaccination
were infrequent: inﬂuenza-like symptoms in 7 subjects (2
TRAP/AS02, 1 RTS,S/AS02, 4 RTS,S + TRAP/AS02), rigors in 1 subject
(RTS,S + TRAP/AS02) and hypesthesia (numbness of arm lasting 2
days) in 1 subject (RTS,S + TRAP/AS02) in the Phase 1 study; ﬂu-like
symptoms in 1 subject (RTS,S + TRAP/AS02) and upper respiratory
tract infection in 1 subject (RTS,S + TRAP/AS02) in the Phase 2 study.
No unsolicited AE with a PB/SU relationship to vaccination was of
Grade 3 intensity.
In both studies, no SAE was reported and no subject was with-
drawn because of an AE. No clinically signiﬁcant hematological,
biochemical, or urine abnormalities were observed.
3.3. Humoral immunogenicity outcomes
3.3.1. Anti-CS response
In both studies, prior to vaccination, no volunteer had anti-CS
antibodies (Table 2). In the Phase 1 study, the post immu-
nization anti-CS GMTs at each timepoint were higher, but not
statistically so, after administration of RTS,S/AS02 compared to
RTS,S + TRAP/AS02. Post Dose 2, the anti-CS GMT  in the RTS,S/AS02
group (85 g/mL [95% CI: 53, 138]) tended to be higher than the
RTS,S + TRAP/AS02 group (56 g/mL [95% CI: 31, 100]) and higher
than that of the corresponding Phase 2 post Dose 2 anti-CS GMT in
the RTS,S + TRAP/AS02 group (35 g/mL [95% CI: 20, 62]).
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Fig. 1. Study ﬂow diagrams.
In the Phase 1 study, all 40 subjects received all 3 doses of study vaccine. In the Phase 2 study, all 35 volunteers who  received study vaccine received both doses; 13 recipients
of  Dose 2 of RTS,S + TRAP/AS02 and 5 recipients of Dose 2 of TRAP/AS02 received vaccine that may  have been transiently stored at subzero temperatures and were excluded
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ubjects and 5 TRAP/AS02 subjects. DOC—day of challenge; PDOC—post day of chal
.3.2. Anti-TRAP response
In the Phase 1 study, an increase in anti-TRAP GMTsas observed after subsequent doses of TRAP/AS02 and
TS,S + TRAP/AS02 (Table 3); GMTs were similar in both groups.
ix months post Dose 3 (day 360), anti-TRAP GMTs had decreased
able 1
ncidence of solicited symptoms reported after all doses (total vaccinated cohort).
Phase 1 safety and immunogenicity 
TRAP/AS02 N = 30 RTS,S/AS02
Local symptoms N % N 
Pain Total 26 87 26 
Grade  3 5 17 6 
Redness Total 4 13 6 
>50  mm 1 3 2 
Swelling Total 6 20 11 
>50  mm 0 0 0 
General symptoms
Arthralgia/joint pain Total 10 33 7 
Grade  3 0 0 0 
Fatigue Total 9 30 11 
Grade  3 0 0 0 
Fever  Total 4 13 5 
>39 ◦C 1 3 2 
Gastrointestinal Total 2 7 4 
Headache Total 8 27 6 
Malaise Total 0 0 1 
Grade  3 0 0 0 
Myalgia Total 17 57 14 
Grade  3 0 0 1 
—number of administered doses.
/%—number/percentage of doses followed by at least one type of symptom.
rade 3 pain—spontaneously painful when moved.
rade 3 general symptoms—adverse event which prevented normal, everyday activities.
ll  Grade 3 symptoms resolved during the 72-h follow-up period following each vaccinatccine for the second dose was administered to the remaining 12 RTS,S + TRAP/AS02
to post Dose 2 GMT  levels in both the TRAP/AS02 and RTS,S + TRAP/
AS02 groups.In the Phase 2 study, the highest anti-TRAP GMTs were observed
post Dose 2 (DOC) in both the TRAP/AS02 and RTS,S + TRAP/AS02
groups; GMTs were similar in both groups. At 134 days post DOC,
study Phase 2 challenge study
 N = 30 RTS,S + TRAP/AS02
N = 60
RTS,S + TRAP/AS02
N = 50
TRAP/AS02 N = 20
% N % N % N %
87 50 83 46 92 20 100
20 10 17 14 28 7 35
20 20 33 13 26 7 35
7 1 2 3 6 0 0
37 14 23 7 14 2 10
0 2 3 0 0 0 0
23 20 33 4 8 0 0
0 1 2 3 6 0 0
37 31 52 16 32 6 30
0 3 5 0 0 0 0
17 20 33 5 10 0 0
7 2 3 0 0 0 0
13 9 15 5 10 0 0
20 16 27 10 20 5 25
3 3 5 12 24 2 10
0 0 0 1 2 0 0
47 38 63 10 20 4 20
3 0 0 0 0 0 0
ion.
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Table  2
Seropositivity rates and GMTs for anti-CS antibodies.
Phase 1 study TRAP/AS02 RTS,S/AS02 RTS,S + TRAP/AS02
Timing N S+ N (%) GMT  [95% CI] (g/mL) N S+ N (%) GMT [95% CI] (g/mL) N S+ N (%) GMT  [95% CI] (g/mL)
Prevaccination 10 0 (0.0) <0.5 10 0 (0.0) 0.1 [0.0, 0.2] 20 0 (0.0) <0.5
14  Days PI (day 14) 10 0 (0.0) <0.5 10 10 (100) 14.9 [6.6, 33.8] 20 18 (90) 9.2 [3.9, 21.6]
14  Days PII (day 42) 10 0 (0.0) <0.5 10 10 (100) 85.4 [52.9, 137.6] 20 19 (95) 55.8 [31.0, 100.4]
14  Days PIII (day 194) 10 0 (0.0) <0.5 10 10 (100) 150.0 [95.2, 236.1] 20 19 (95) 59.8 [27.7, 129.1]
6  Months PIII (day 360) 10 0 (0.0) <0.5 10 10 (100) 72.4 [39.5, 132.7] 20 18 (90) 29.0 [11.1, 75.6]
Phase 2 study RTS,S + TRAP/AS02 TRAP/AS02
Timing N S+ N (%) GMT  [95% CI] (g/mL) N S+ N (%) GMT  [95% CI] (g/mL)
Prevaccination 12 0 (0) – 5 0 (0) –
14  Days PI (day 14) 12 10 (83) 7.9 [1.7, 36.2] 5 1 (20) <0.5
28  Days PI (day 28) 12 10 (83) 8.5 [2.3, 31.5] 5 0 (0) <0.5
16–27 Days PII (DOC) 11 11 (100) 35.1 [19.7, 62.2] 5 0 (0) <0.5
DOC  + 134 days 10 9 (90) 6.2 [2.6, 14.8] 5 0 (0) <0.5
S+—seropositivity deﬁned as ≥1.0 g/mL of anti-CS antibody. Anti-CS antibody titers of <1 g/mL were assigned a value of 0.5 g/mL for the purpose of GMT  calculation.
N—number of subjects tested (Phase 1 study, ITT cohort; Phase 2 study, subjects receiving normal vaccine at Dose 2 in modiﬁed ITT immunogenicity cohort).
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DI,  PII and PIII—post Dose 1, post Dose 2 and post Dose 3.
OC—day of challenge.
nti-TRAP GMTs had decreased but were still above post Dose 1
alues in both vaccine groups.
.3.3. Cell mediated immunogenicity outcomes
In the Phase 1 study, antigen speciﬁc proliferative responses to
TS,S in recipients of RTS,S/AS02 or RTS,S + TRAP/AS02 and to TRAP
n recipients of TRAP/AS02 or RTS,S + TRAP/AS02 were markedly
levated over baseline values. Proliferation to RTS,S was similar in
oth the RTS,S/AS02 and RTS,S + TRAP/AS02 groups and to TRAP
n both the TRAP/AS02 and RTS,S + TRAP/AS02 groups (see Supple-
entary Appendix). Cellular responses were boosted by the third
accination and responses persisted at day 360.
Measurements of IFN- and IL-5 in culture supernatant in
esponse to antigen-speciﬁc stimulation showed substantial induc-
ion post second vaccination; no meaningful increase was  observed
ost third vaccination. No real differences in RTS,S stimulated
esponses were observed between RTS,S and RTS,S/TRAP vacci-
ated groups (see Supplementary Appendix).In the Phase 2 study, RTS,S stimulated IFN- responses in PBMC
ultures derived from subjects vaccinated with RTS,S + TRAP/AS02
reatly exceeded baseline responses (Fig. 2). RTS,S did not elicit
FN- responses in PBMC cultures from subjects vaccinated with
able 3
MTs for anti-TRAP antibodies.
Phase 1 studya TRAP/AS02 RTS,
Timing N GMT  [95% CI] (EL.U/mL) N 
14 days PI (Day 14) 8 304 [129,721] – 
14  days PII (Day 42) 10 2251 [1050,4828] – 
14  days PIII (Day 194) 10 4410 [3136,6201] 2 
6  months PIII (Day 360) 10 1879 [1472,2397] 6 
Phase  2 study RTS,S + TRAP/AS02 
Timing N GMT  [95% CI] (E
14 Days PI (day 14) 12 79 [16,38
28  Days PI (day 28) 12 22 [3,18
16–27  Days PII (DOC) 11 2237 [1052,475
DOC  + 134 days 11 178 [23,136
a RTS,S/AS02 group: anti-TRAP antibody assay results for any subject at 14 days post D
vailable.
—number of subjects tested (Phase 1 study, ITT cohort; Phase 2 study, subjects receiving
I,  PII and PIII—post Dose 1, post Dose 2 and post Dose 3.
OC—day of challenge.TRAP/AS02. TRAP-speciﬁc IFN- responses were observed in PBMC
cultures from RTS,S + TRAP as well as TRAP vaccinated subjects, but
not in pre-vaccination PBMC cultures.
Analysis of IL-4 responses in parallel cultures of PBMC from pre-
and post-vaccinated subjects showed a similar pattern of reactiv-
ity (Fig. 3). Pre-immune PBMC showed no notable responses to
either RTS,S or to TRAP. Post vaccination IL-4 responses elicited
with RTS,S and TRAP were antigen-speciﬁc in that TRAP recalled
responses in TRAP and RTS,S + TRAP recipients, whereas RTS,S
recalled responses only in RTS,S + TRAP vaccinees. Of note, while
PBMC from RTS,S + TRAP recipients showed higher IFN- responses
to RTS,S than TRAP, results for IL-4 responses to both antigens were
similar.
3.4. Vaccine efﬁcacy
Of the 24 volunteers who underwent challenge, patent para-
sitemia developed in 10 of 11 RTS,S + TRAP/AS02 vaccinees, all 5
TRAP/AS02 vaccinees, and all 8 infectivity controls (Fig. 4). Fisher’s
exact tests of the proportion of subjects infected indicated that nei-
ther vaccinated group differed from control (p = 1.0). The median
pre-patent period from challenge to infection was 13.0, 11.0 and
S/AS02 RTS,S + TRAP/AS02
GMT  [95% CI] (EL.U/mL) N GMT  [95% CI] (EL.U/mL)
– 16 341 [236,494]
– 20 2178 [1308,3627]
235 [189,292] 20 3152 [2212,4491]
231 [121,440] 20 1411 [886,2247]
TRAP/AS02
L.U/mL) N GMT  [95% CI] (EL.U/mL)
9] 5 7 [0.1, 547]
7] 5 20 [0.3, 1362]
9] 5 1877 [1468,2399]
7] 5 628 [328,1204]
ose 1 or 14 days post Dose 2 and for many subjects at other timepoints were not
 normal vaccine at Dose 2 in modiﬁed ITT immunogenicity cohort).
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Fig. 2. IFN- ELISPOT activity recalled with RTS,S or TRAP.
IFN- producing cells measured by Elispots after in vitro stimulation of PBMCs with RTS,S or TRAP before vaccination (Pre) and at 2 weeks post second vaccination (Post)
from  subjects vaccinated with RTS,S + TRAP/AS02 (RTS,S + TRAP) vs with TRAP/AS02 (TRAP). The individual Elispot responses, expressed as the number of IFN-+ cells per
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a06 PBMCs, are shown as dots/triangles and overall the minimum—Quartile1–med
epresented by a unique symbol and this symbol is used for all graphs.
2.0 days for the RTS,S + TRAP/AS02, TRAP/AS02 and infectivity con-
rol groups, respectively (log rank test: p = 0.096 RTS,S + TRAP/AS02
s control, p = 0.661 TRAP/AS02 vs control).
. Discussion
Both studies demonstrated the combination vaccine
TS,S + TRAP/AS02 had an acceptable safety proﬁle and was
enerally well tolerated. Although not designed as non-inferiority
rials and thus signiﬁcantly underpowered to permit a formal
onclusion, the anti-CS IgG responses in subjects who  received
oth RTS,S + TRAP were substantially lower – at every time point
easured – than in those who received RTS,S alone. While there
ay be alternative explanations, immune interference between
RAP and RTS,S must be considered as a leading explanation for
he failure to see protection in the RTS,S/TRAP group. We  have
o real understanding as to how the anti-TRAP antibodies that
ere induced impacted on the anti-CS responses. While a speciﬁc
orrelate of protection for RTS,S has not been identiﬁed, analyses
f potential correlates of protection consistently emphasize the
ssociation between protection and high levels of CS antibodies
t the time of sporozoite exposure [2–5]. In the Phase II studyuartile-3 and maximum values are represented as well. Each individual subject is
reported here, peak IgG responses to CS in the RTS,S/TRAP group
were approximately 50% of what would have been typically
observed in individuals receiving RTS,S alone. In contrast to CS,
TRAP appears to be inherently more immunogenic, and in both the
Phase 1 and Phase 2 studies, similar anti-TRAP humoral responses
were observed with the combination and the component vaccines.
Immunological interference between antigens in combination
vaccines is a well-known although highly unpredictable phe-
nomenon that can occur even in the presence of a potent adjuvant.
In the Phase 1 study, low levels of cross-reactive anti-TRAP antibody
responses observed in the RTS,S/AS02 group may  be due to anti-
bodies directed against the thrombospondin-like type 1 sequence
in the C terminus of CS [39,40,25]. At this point, there is no way
of knowing conclusively as to whether or not measured or unmea-
sured immune responses to TRAP impacted on other aspects of the
immune response induced by RTS,S.
In the Phase 1 study, the RTS,S- and TRAP-speciﬁc responses
evaluated by proliferative responses, and IFN- and IL-5 secretion
in the culture supernatant, were similar for vaccinees who received
the combination RTS,S + TRAP/AS02 and for vaccinees who  received
either RTS,S/AS02 or TRAP/AS02. At the time of evaluation in 1999,
assays were not in place to measure CS-speciﬁc cellular responses.
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Fig. 3. IL-4 ELISPOT activity recalled with RTS,S or TRAP.
IL-4 producing cells measured by Elispots after in vitro stimulation of PBMCs with RTS,S or TRAP before vaccination (Pre) and at 2 weeks post second vaccination (Post)
from  subjects vaccinated with RTS,S + TRAP/AS02 (RTS,S + TRAP) vs with TRAP/AS02 (TRAP). The individual Elispot responses, expressed as the number of IFN-+ cells per
1 ian—Q
r
H
r
t
e
F
v06 PBMCs, are shown as dots/triangles and overall the minimum—Quartile1–med
epresented by a unique symbol and this symbol is used for all graphs.ence, the RTS,S-speciﬁc responses recorded were the combined
esponses speciﬁc to both the HBs and CS antigen components of
he RTS,S vaccine. In the Phase 2 trial, the vaccination regimens
licited low RTS,S- and TRAP-speciﬁc T cell responses, measured
ig. 4. Protection and time to parasitemia. Log rank test: p = 0.096 RTS,S + TRAP/AS02
s control, p = 0.661 TRAP/AS02 vs control.uartile-3 and maximum values are represented as well. Each individual subject is
by IFN- ELISPOT assay, and were notably lower when compared
to other studies using the same methodology [5,38].
After challenge, all infectivity controls, 5 of 5 TRAP/AS02
vaccinees and 10 of 11 RTS,S + TRAP/AS02 vaccinees developed par-
asitemia. There was  no evidence of any prevention or delay of
parasitemia by TRAP/AS02. The absence of a signiﬁcant delay or pre-
vention of parasitemia by RTS,S + TRAP/AS02 contrasts sharply with
the demonstration of prevention of parasitemia by published Phase
2 studies of 1 or 2 doses of RTS,S/AS02 in malaria-naïve adults fol-
lowing malaria challenge. Speciﬁcally, a single dose of RTS,S/AS02
protected 3 of 10 subjects, and 2 doses of RTS,S/AS02 protected 7
of 14 subjects in one trial against experimental malaria challenge
[2] and in another trial protected 8 of 19 subjects [3].
In the challenge model [1–5] and in ﬁeld studies in adults [6]
and children [8,10,41–44] vaccinated with the candidate RTS,S/AS
vaccine, an association between anti-CSP central repeat region anti-
body and protection was  observed. Although two  pediatric ﬁeld
trials reported a lack of association, the very high titers achieved
in these children and the relatively short period of follow-up may
have limited the ability to discriminate on the basis of differen-
tial CS responses [7,9]. In the challenge model, protected compared
to non-protected recipients of RTS,S/AS have also demonstrated
higher CS-speciﬁc CD4+ T cell and IFN- ELISPOT responses [5,38]
and in a ﬁeld trial in children, higher CS-speciﬁc TNF CD4+ T cells
[44].
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Other investigators have clearly established that TRAP is a valid a
alaria vaccine candidate, although its ability to confer protection
s entirely dependent on the way the antigen is delivered [45]. It
s clear from this trial that antibodies and CD4+ T cell responses
re insufﬁcient, but when TRAP is delivered using heterologous
rime boost such that potent CD8+ T cell responses are gener-
ted, compelling protection has been reported [46]. Based on these
bservations we are currently exploring whether the combination
f RTS,S/AS01 plus ChAd63/MVA ME-TRAP will lead to enhanced
evels of protection against experimental malaria challenge.
We  recognize that there are a number of limitations associated
ith the challenge study, most notably a small sample size, which
as further impacted by the exclusion of 18 subjects from the chal-
enge phase. Further, the lack of an RTS,S/AS02 comparator does
revent direct, within-study efﬁcacy comparisons between RTS,S,
TS,S/TRAP, and TRAP formulations. We  conclude, within the con-
traints of the small sample size, that the presence of TRAP antigen
ay  have interfered with vaccine efﬁcacy previously observed with
his regimen of RTS,S/AS02, and that future TRAP-based vaccines
hould consider employing alternative vaccine platforms.
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